Connective
Tissue Disease Market Research Report information: Diagnosis (X-ray
Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal
Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User
- Global forecast till 2023
Connective tissues are a
group of cellular congregations that provide support and structure to the human
body. Connective tissue disease is a group of disorders which involves these
protein rich tissues. Protein rich tissues play an important role of supporting
organs and other parts of the body. Connective tissue disorders involves
multiple organs and organ systems such as, skin, joints, muscles, lungs,
kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200
disorders affect the connective tissues. According to a study published in Pan
African Medical Journal in 2017, it is found that mixed connective tissue
disorders are more frequent among Asians, and in the African population. It is
also reported that among Asian population, the condition is more prevalent in
China, and Japan. In the European region, the disorder is more prevalent in
Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective
tissue disease disorder market is slated to grow at a promising CAGR of
11.5% over the forecast period of 2017-2023. The
cause of the disease is unknown and there's no cure for connective
tissue disease yet, but medications are
present to manage the signs and symptoms. CTDs include a large number of
disorders which can affect different organs of the body. There is broad variability in disorders among patient
suffering from CTDs.
It is
estimated that connective tissue disease market is expected to grow at a CAGR
11.5% during the forecast period of 2017-2023.
A significant increase in the research and
development efforts to find treatment and cure for CTDs have aided the growth
of the market. Various therapy trials are underway
which have been able to identify
promising novel approaches to treat CTDs
and are expected to boost the growth of the market. Rising prevalence of CTDs
across the globe, especially in women has propelled the growth of the market.
Additionally, support from governments across
the world along with funds for R&D from the private industry is also a key driver of the growth of the market.
With the increase in awareness and
acceptance among the general population
about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising
expenditure on healthcare, high unmet medical needs of the current treatment
and growing prevalence of CTDs in Asia and Africa are expected to promote the
growth of the market. However, the
growth of the market might be hindered by
lack of a knowledgeable workforce, inadequate research and development
infrastructure, lack of funds in middle and low-income
countries.
Key Players
Some of key the players in the market are
·
Abbott Laboratories
·
Bayer AG
·
F. Hoffmann-La Roche Ltd
·
Pfizer
·
AutoImmune Inc.
·
Johnson & Johnson
·
Amgen Inc.
·
AstraZeneca
·
Eli Lilly and Company
·
Biogen
·
LUPIN
Segmentation
The connective tissue disease market is
segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is
segmented into physical examination, X-ray examination, ANA (Antinuclear
Antibody Test), and others.
On the basis of treatment, market is classified
into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids,
antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is
segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective
tissue disease market owing to the rising awareness among people, and
increasing healthcare expenditure. As per the facts suggested by the Centers
for Disease Control and Prevention (CDC), out of the total annual healthcare
expenditure, 86% is for people with chronic health conditions in the United
States.
Europe holds the second position in the
connective tissue disease market. It is expected that the support provided by
government bodies for research & development and improvement in
reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing
market connective tissue disease, owing to a huge patient pool, developing
healthcare technology, and rising healthcare expenditure in some countries
within this region. According to the Australian Institute of Health and
Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4
billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest
market for connective tissue disease due to lack of technical knowledge and
poor medical facilities.
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
No comments:
Post a Comment